Related Experiment Video
Updated: May 28, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
DNA repair and synthetic lethality
Gong-She Guo1, Feng-Mei Zhang, Rui-Jie Gao
1School of Public Health, Shandong University, Jinan 250012, China.
Abstract:
Tumors often have DNA repair defects, suggesting additional inhibition of other DNA repair pathways in tumors may lead to synthetic lethality. Accumulating data demonstrate that DNA repair-defective tumors, in particular homologous recombination (HR), are highly sensitive to DNA-damaging agents. Thus, HR-defective tumors exhibit potential vulnerability to the synthetic lethality approach, which may lead to new therapeutic strategies. It is well known that poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitors show the synthetically lethal effect in tumors defective in BRCA1 or BRCA2 genes encoded proteins that are required for efficient HR. In this review, we summarize the strategies of targeting DNA repair pathways and other DNA metabolic functions to cause synthetic lethality in HR-defective tumor cells.
Insights
Targeting DNA repair defects in tumors, especially homologous recombination (HR) deficiency, offers synthetic lethality strategies. Inhibiting poly (ADP-ribose) polymerase (PARP) in HR-defective tumors presents a promising therapeutic approach.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Tumors frequently exhibit DNA repair defects, creating vulnerabilities.
- Homologous recombination (HR) deficiency is a common DNA repair defect in tumors.
- DNA repair defects suggest potential for synthetic lethality by inhibiting other pathways.
Purpose of the Study:
- To review strategies for targeting DNA repair pathways in HR-defective tumors.
- To explore the synthetic lethality approach for cancer therapy.
- To highlight the vulnerability of HR-defective tumors to specific inhibitors.
Main Methods:
- Literature review of DNA repair pathways and synthetic lethality.
- Analysis of poly (ADP-ribose) polymerase (PARP) inhibitors' effects.
- Examination of targeting DNA metabolic functions in HR-defective cells.
Main Results:
- HR-defective tumors show heightened sensitivity to DNA-damaging agents.
- Poly (ADP-ribose) polymerase (PARP) inhibitors induce synthetic lethality in BRCA1/2-defective tumors.
- Targeting DNA repair offers viable therapeutic strategies for specific tumor types.
Conclusions:
- Synthetic lethality by targeting DNA repair pathways is a promising strategy for HR-defective tumors.
- PARP inhibitors represent a key therapeutic class for tumors with HR deficiencies.
- Further research into DNA repair inhibition can yield novel cancer treatments.
Related Concept Videos
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair
Nucleotide Excision Repair
Fixing Double-strand Breaks
Fixing Double-strand Breaks
Overview of DNA Repair
Chemically...

